SCHEMBL22859552

SCHEMBL22859552

Cc1cnc2cc(C(=O)O)sc2c1C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN3B O60391 3/20 0.59
GRIN1 Q05586 3/20 0.59
GRIN2C Q14957 3/20 0.59
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.46
DAO P14920 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.46
HCAR2 Q8TDS4 1/20 0.44
GPR35 Q9HC97 2/20 0.43
GLA P06280 2/20 0.40
PKM P14618 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22859510 0.86 GRIN3B (0.55) GRIN3BGRIN1GRIN2CKDM4EALDH1A1
SCHEMBL22859595 0.84 GRIN3B (0.60) GRIN3BGRIN1GRIN2CKDM4EALDH1A1
SCHEMBL23011699 0.80 GRIN3B (0.49) GRIN3BGRIN1GRIN2CGRIN2DGRIN2A
SCHEMBL29605522 0.79 GRIN3B (0.67) GRIN3BGRIN1GRIN2CGRIN2DGRIN2A
SCHEMBL22859470 0.77 GRIN3B (0.59) GRIN3BGRIN1GRIN2CKDM4EALDH1A1
SCHEMBL29368421 0.77 GRIN3B (0.59) GRIN3BGRIN1GRIN2CKDM4EALDH1A1
SCHEMBL23011551 0.76 GRIN3B (0.52) GRIN3BGRIN1GRIN2CKDM4EALDH1A1
SCHEMBL22859689 0.75 GRIN3B (1.00) GRIN3BGRIN1GRIN2CGRIN2DGRIN2A
SCHEMBL29365569 0.75 GRIN3B (1.00) GRIN3BGRIN1GRIN2CGRIN2DGRIN2A
SCHEMBL28691650 0.75 GRIN3B (1.00) GRIN3BGRIN1GRIN2CGRIN2DGRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11466027-B2 Modulators of the NMDA receptor H. LUNDBECK A/S (DK) 2022-10-11 US disclosed
US-11466027-B2 Modulators of the NMDA receptor H. LUNDBECK A/S (DK) 2022-10-11 US disclosed
US-20220213117-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2022-07-07 US disclosed
US-20220213117-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2022-07-07 US disclosed
US-11358971-B2 Prodrugs of modulators of the NMDA receptor H. LUNDBECK A/S (DK) 2022-06-14 US disclosed
US-11358971-B2 Prodrugs of modulators of the NMDA receptor H. LUNDBECK A/S (DK) 2022-06-14 US disclosed
EP-3994141-A1 MODULATORS OF THE NMDA RECEPTOR H. Lundbeck A/S (DK) 2022-05-11 EP disclosed
EP-3994140-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. Lundbeck A/S (DK) 2022-05-11 EP disclosed
CN-114008053-A Prodrugs of NMDA receptor modulators H.隆德贝克有限公司 2022-02-01 CN disclosed
CN-114008054-A NMDA receptor modulators H.隆德贝克有限公司 2022-02-01 CN disclosed
US-20210047342-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-02-18 US disclosed
US-20210047342-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-02-18 US disclosed
WO-2021001420-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-01-07 WO disclosed
WO-2021001423-A1 MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-01-07 WO disclosed
WO-2021001423-A1 MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-01-07 WO disclosed
US-20210002292-A1 MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-01-07 US disclosed
US-20210002292-A1 MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-01-07 US disclosed
WO-2021001420-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2021-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11466027-B2 Modulators of the NMDA receptor GRIN1, GRIN2A, GRIN3A GRIN3B 5/4885GRIN1 1/4885GRIN2C 8/4885
US-11358971-B2 Prodrugs of modulators of the NMDA receptor GRIN3A, GRIN1, GRIN2A GRIN3B 5/4885GRIN1 2/4885GRIN2C 6/4885
US-20210002292-A1 MODULATORS OF THE NMDA RECEPTOR GRIN1, GRIN2A, GRIN3A GRIN3B 5/4885GRIN1 1/4885GRIN2C 8/4885
US-20210047342-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR GRIN3A, GRIN1, GRIN2A GRIN3B 5/4885GRIN1 2/4885GRIN2C 6/4885
US-20220213117-A1 PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR GRIN3A, GRIN1, GRIN2A GRIN3B 5/4885GRIN1 2/4885GRIN2C 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.